Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday

Key Points

• Arcturus Therapeutics will report Q1 2026 results after the market close on Thursday, May 7 at 4:30 PM ET, with analysts forecasting ($1.0133) EPS and $6.296M in revenue.
• The company recently missed estimates (reported ($1.03) vs. consensus ($0.92)), carries a sharply negative net margin (~80%), and analysts expect about -$4 EPS for the current and next fiscal year.
• ARCT opened at $8.62 with a market cap near $245M and a 12‑month range of $5.85–$24.17; institutional investors own ~94.54% of the stock and the Street’s consensus is a "Moderate Buy" with an average price target of $29.50.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) is projected to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.0133) per share and revenue of $6.2960 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.11). Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $14.32 million. On average, analysts expect Arcturus Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcturus Therapeutics Trading Up 2.6%

ARCT stock opened at $8.62 on Friday. The firm has a 50 day moving average of $7.83 and a 200-day moving average of $8.27. The firm has a market capitalization of $244.98 million, a P/E ratio of -3.62 and a beta of 2.44. Arcturus Therapeutics has a 12 month low of $5.85 and a 12 month high of $24.17.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth approximately $210,000. Panagora Asset Management Inc. bought a new position in shares of Arcturus Therapeutics during the fourth quarter valued at about $213,000. Aristides Capital LLC bought a new position in shares of Arcturus Therapeutics during the fourth quarter valued at about $161,000. Alps Advisors Inc. boosted its holdings in shares of Arcturus Therapeutics by 78.0% during the fourth quarter. Alps Advisors Inc. now owns 23,325 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 10,224 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company's stock worth $136,000 after purchasing an additional 1,567 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ARCT. Weiss Ratings upgraded shares of Arcturus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, April 21st. Piper Sandler reduced their target price on Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, March 4th. Citigroup decreased their target price on Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. B. Riley Financial assumed coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They set a "buy" rating and a $22.00 price objective for the company. Finally, Roth Mkm started coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 22nd. They issued a "buy" rating and a $20.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.50.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.